Podcasts about Pharma

How's the cup hangover treating everyone? Doesn't It feels good to be champions? In this episode Clay and Valair discuss our U.S Open Cup win and draw in Montreal.  Thanks for listening! 

Jennifer J. Brown is a scientist, a writer, and a mother who never got the luxury of separating those roles. Her memoir When the Baby Is Not OK: Hopes & Genes is a punch to the gut of polite society and a medical system that expects parents to smile through trauma. She wrote it because she had to. Because the people who gave her the diagnosis didn't give her the truth. Because a Harvard-educated geneticist with two daughters born with PKU still couldn't get a straight answer from the very system she trained in.We sat down in the studio to talk about the unbearable loneliness of rare disease parenting, the disconnect between medical knowledge and human connection, and what it means to weaponize science against silence. She talks about bias in the NICU, the failure of healthcare communication, and why “resilience” is a lazy word. Her daughters are grown now. One's a playwright. One's an artist. And Jennifer is still raising hell.This is a conversation about control, trauma, survival, and rewriting the script when the world hands you someone else's lines.Bring tissues. Then bring receipts.RELATED LINKS• When the Baby Is Not OK (Book)• Jennifer's Website• Jennifer on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What do ESPN mobile games, NHL jumbotrons, and pharma cleanrooms all have in common? Ben Davis.In this episode, Ben Davis — serial entrepreneur and CEO of Phizzle — shares how he went from selling CAD software in Silicon Valley to pioneering the future of drug manufacturing automation. From building ESPN's first branded mobile games pre-iPhone, to engineering a cleanroom-compliant hardware device (when his company was supposed to be software only), Ben reveals what it takes to stay ahead of tech revolutions.We talk startups, pivots, and solving billion-dollar problems no one else wants to touch — all with Phizzle's signature grit.

On this episode of the Trade Guys, we look at a slew of recent tariff announcements, including on furniture, pharmaceuticals, and foreign movies. We also cover China's relinquishing of “special and differential” WTO treatment and the expiration of the African Growth and Opportunity Act (AGOA).

Host Michael Azevedo is joined on this episode is Clay Tweel, director of a powerful new documentary called "The Bitter Pill."    Clay's film—which debuted on PBS on 9/22 and will be available to stream on PBS digital until December 10-- follows the charismatic West Virginian plaintiff attorney Paul Farrell, Jr, as he wages a legal war against some of the world's largest pharmaceutical companies in a landmark battle fueled by personal stakes.    A powerful chronicle of justice, accountability, and resilience, the Bitter Pill is set in Farrell's hometown, Cabell County, West Virginia, a community at the epicenter of America's opioid epidemic, where 20% of babies are born addicted to opioids.    A plaintiff attorney, Farrell is determined to recover damages, bring justice to his neighbors, and rebuild a community ravaged by corporate greed.    Making Media Now is sponsored by Filmmakers Collaborative, a non-profit organization dedicated to supporting media makers from across the creative spectrum. From providing fiscal sponsorship to presenting an array of informative and educational programs, Filmmakers Collaborative supports creatives at every step in their journey. About the host: www.writevoicecreative.com and https://www.linkedin.com/in/michael-azevedo/   Sound Engineer: A.J. Kierstead

The Boys in Gold lifted the first trophy in club history by defeating Austin FC in the Open Cup final. The Pharma boys recap and react to the historic achievement.

Tariffs, drug pricing reform, a government shutdown and a major turnover at one of the world’s largest drugmakers all converged this week, leaving plenty to unpack for the industry as it heads into fall. Greater clarity on President Donald Trump’s tariff and pricing strategies has likely come as something of a relief for those companies operating in the U.S., but that news was tempered by a shutdown of the federal government on Wednesday. Meanwhile, big changes are likely on the way at GSK, whose longtime CEO Emma Walmsley is headed for the exit. In this week’s episode of "The Top Line," we break down some of the biggest stories across Fierce Pharma for the week—which may very well be some of the biggest stories of the year—touching on critical policy updates in the U.S., the furloughing of federal employees at agencies like the FDA and NIH and the imminent departure of GSK’s chief executive. Fierce Life Sciences’ Ben Adams sits down with Fierce Pharma's Fraiser Kansteiner to discuss the latest headlines and go over the key points from each major development that has played out. To learn more about the topics in this episode: FDA avoids the worst amid government shutdown, but new applications put on hold NIH research grinds to a halt as government shuts down Pfizer offers price concessions, $70B US outlay in Trump's 'most favored nation' push Trump's pharma tariffs on hold amid administration's effort to secure pricing concessions, industry investment: Stat GSK's Emma Walmsley to step down as CEO in shock move, giving way to commercial lead Luke Miels See omnystudio.com/listener for privacy information.

New treatment approved for primary humoral immunodeficiency; eyedrops now available to improve near vision; Tremfya approval expanded to include pediatric plaque psoriasis, psoriatic arthritis; FDA fast tracks treatments for methamphetamine intoxication, Alzheimer disease.

This episode of Standard Deviation features Oliver Bogler in conversation with Dr Na Zhao, a cancer biologist caught in the crossfire of science, politics, and survival. Na's life reads like a brutal lab experiment in persistence.She grew up in China, lost her mother and aunt to breast cancer before she turned twelve, then came to the United States to chase science as both an immigrant and a survivor's daughter. She worked two decades to reach the brink of independence as a cancer researcher, only to watch offers and grants vanish in the political chaos of 2025.Oliver brings her story into sharp focus, tracing the impossible climb toward a tenure-track position and the human cost of a system that pulls the ladder up just as people like Na reach for it. This conversation pulls back the curtain on the NIH funding crisis, the toll on early-career scientists, and what happens when personal tragedy fuels professional ambition.Listeners will walk away with a raw sense of how fragile the future of cancer research really is, and why people like Na refuse to stop climbing.RELATED LINKSDr Zhao at Baylor College of MedicineDr Zhao on LinkedInDr Zhao's Science articleIndirect Costs explained by US CongressFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

APAC stocks were firmer, with gains across the board following a positive handover from Wall Street, where tech outperformed, whilst the US jobs reports this week look set to be delayed after CR votes failed again on Wednesday, as expected.Fitch said a US government shutdown does not have near-term implications for the ‘AA+'/stable US sovereign rating; S&P estimated the shutdown could reduce GDP growth by 0.1–0.2 ppts per week.10yr JGB futures came under pressure after the 10yr JGB auction, which printed a lower cover ratio than the prior sale and followed the recent 2yr JGB auction that saw the weakest cover ratio since 2009.The US will provide Ukraine with intelligence for missile strikes deep inside Russia, and US officials are asking NATO allies to provide similar support, via WSJ.Looking ahead, highlights include Swiss CPI (Sep), EZ Unemployment (Aug), US Challenger Layoffs (Sep), BoJ's Uchida, Fed's Logan, ECB's de Guindos, BoC's Mendes, Supply from Spain, France, and the UK.Due to the US government shutdown, the following US data will not be released: Weekly Claims, Factory Orders (Aug), Durable Goods Rev. (Aug).Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Pharma stocks breaking out, as President Trump inks a drug pricing deal. What it means for the group, and how the broader health care sector is breathing a sigh of relief. Plus Elon Musk and some bingeing backlash. Why the billionaire is calling for customers to cancel their subscriptions for the streaming giant, and the show creator causing the drama. Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ok—we are burning daylight—and we need to get rolling   Number One— President Trump made a deal with Pharma giant Pfizer to lower drug prices for all Americans—it is a huge deal to help those with better healthcare and pay less money—   Number Two— 800 Generals, Admirals and flag officers gathered in Virginia—to get marching orders for the future of the United States military—and boy did they get it—and its going to be the end of woke BS for fighting men and women—   Number Three— If you asked me what the greatest threat to our nation was a year ago, I might've told you our open border: we had millions of gotaways pouring in – an untold number of terrorist threats setting up shop in hometowns across America – major cities caving under the influx.

Join Dr. Brendan McCarthy, as he dives into Part 2 of our series on understanding the divide in modern medicine. In this episode, Dr. McCarthy explores: How education, corporate influence, and lobbying have shaped medicine and nutrition advice The history and impact of the food pyramid and dietary guidelines Why trust in traditional medicine has eroded and how alternative approaches gained popularity The role of pharmaceutical advertising and conference influence on medical practice Steps to rebuild trust and prioritize patient-centered care   Dr. McCarthy emphasizes accountability, understanding science objectively, and always keeping the patient's well-being at the center of care.  

Das war selbst für US-Verhältnisse bizarr: Der Verteidigungsminister ließ seine Generalität einfliegen, um sie über Fitnessnormen zu belehren – eine besondere Form der Machtdemonstration.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Metsera's mid-stage obesity drug, met-097i, has shown "very encouraging" efficacy, supporting Pfizer's proposed $4.9 billion buyout of the company. The drug's performance is seen as positive by BMO Capital Markets. In other news, drug manufacturers are increasingly utilizing artificial intelligence throughout the drug production process, moving from using AI for specific operations to optimizing the entire production process. Additionally, Crystalys, backed by Novo, has debuted with $205 million to tackle gout with its drug dotinurad. The FDA recently singled out Aurinia Pharmaceuticals in a LinkedIn post about surrogate endpoints for lupus nephritis drugs, criticizing companies for not conducting post-approval studies to demonstrate benefits on hard clinical endpoints. Larimar's Friedreich's ataxia drug has faced concerns about anaphylaxis, causing shares to fall. GSK's CEO Emma Walmsley has stepped down after 9 years, resealing pharma's glass ceiling. Upcoming webinars will focus on topics such as mRNA medicine and biopharma in an age of deregulation.

Katie Henry has seen some things. From nonprofit bootstraps to Big Pharma boardrooms, she's been inside the machine—and still believes we can fix it. We go deep on her winding road from folding sweaters at J.Crew to launching a vibrator-based advocacy campaign that accidentally changed the sexual health narrative in breast cancer.Katie doesn't pull punches. She's a born problem solver with zero tolerance for pink fluff and performative empathy. We talk survivor semantics, band camp trauma, nonprofit burnout, and why “Didi” is the grandparent alter ego you never saw coming.She's Murphy Brown with a marimba. Veronica Sawyer in pharma. Carla Tortelli with an oncology Rolodex. And she still calls herself a learner.This is one of the most honest, hilarious, and refreshingly real conversations I've had. Period.RELATED LINKS:Katie Henry on LinkedInKatie Henry on ResearchGateLiving Beyond Breast CancerNational Breast Cancer CoalitionFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Nashville SC win their final game before they travel to Austin to play in the U.S Open Cup final. This was the perfomance the group needed before they take another shot at their first piece of silverware.    Thanks for listening! See y'all in Austin. 

30'000 Stellen schuf die Pharmabranche in den letzten 25 Jahren. Es ist zudem die wichtigste Exportbranche der Schweiz. Ist diese Entwicklung mit den Pharmazöllen der USA von 100 Prozent zu Ende? Stephan Mumenthaler ist Direktor des Verbandes für Pharma und Chemie Scienceindustries. Ab 1. Oktober sollen neue Pharmazölle in den USA in Kraft treten. Zudem lief die Frist aus, die Trump 17 Pharmafirmen gesetzt hatte, um tiefere Medikamentenpreise anzusetzen. Was bedeutet dies nun für die Schweiz? Wie sind Schweizer Firmen betroffen? Die grossen und kleinen? Gibt es eine Abwanderung von Arbeits- und Forschungsplätzen in die USA? Wird damit die Erfolgsgeschichte der Schweizer Pharmaindustrie gestoppt? Der Wirtschaftsverband der Pharma und Chemie, Scienceindustries, sieht auch die Versorgungssicherheit gefährdet. Stephan Mumenthaler ist Direktor von Scienceindustries und zu Gast im Tagesgespräch bei Karoline Arn.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Genmab has acquired Merus, a rising star in the field of oncology, for $8 billion. The acquisition includes Merus' bispecific antibody, petosemtamab, which targets EGFR and LGR5 and has shown potential for head-and-neck cancer. In other news, GSK CEO Emma Walmsley is stepping down after nine years, with Chief Commercial Officer Luke Miels set to replace her next year. The FDA's decision to disclose complete response letters in real-time has raised questions about transparency and the agency's role. Additionally, Biogen has shuffled staff after ending work on AAV, while Heidelberg has cut 75% of its staff after missed royalty payments.The FDA's real-time disclosure of complete response letters benefits investors by providing greater visibility into regulatory decisions. In September, the FDA's actions included boosting Keytruda while rejecting two spinal muscular atrophy therapies due to manufacturing issues. A judge's ruling on the FDA's authority over laboratory-developed tests reflects the impact of a recent Supreme Court decision. Six FDA decisions to watch for in Q4 could have significant implications for the biopharma industry and patients. Recent developments include positive results for an immuneering asset in pancreatic cancer, FDA approval for Lilly's oral SERD for breast cancer, and positive outcomes for uniQure's Huntington's therapy. Additionally, the FDA is streamlining development of cell, gene, and regenerative therapies. Other news includes the revival of a dormant drug as a potential autism treatment, setbacks in obesity studies, and unexpected rejections for certain therapies. Upcoming webinars and job opportunities are also highlighted.Listeners are encouraged to provide feedback on topics they would like to see covered in future episodes.

Ohne Aktien-Zugang ist's schwer? Starte jetzt bei unserem Partner Scalable Capital. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Merger Monday bei EA, Occidental, Genmab und Merus. TotalEnergies und Lufthansa entlassen. Uber und Meta haben große Side-Gigs. Trump mag US-Filme & Cannabis. Moonlake crasht. Lyft (WKN: A2PE38) oder Uber? Wir klären auf. Was haben TikTok, die Software AG, EA, Dell, die UFC und Manchester City gemeinsam? Silver Lake und Egon Durban! Diesen Podcast vom 30.09.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

It's been just over a week since the Trump administration very publicly claimed that Tylenol usage is linked to an increased rate of autism.Based on dubious evidence, the White House asserted that acetaminophen – the active ingredient in Tylenol – is what's behind the “current autism epidemic.”For all of the bluster and upheaval that arose from the communications coming out of 1600 Pennsylvania Avenue, there are real lessons to be learned for health brands and medical marketers on a professional level.However, on a personal level, there is also plenty that can be learned from those living on the spectrum or caring for those who do.On this episode, managing editor Jack O'Brien moderates an in-depth, critical conversation about the Tylenol-autism controversy between editor-in-chief Jameson Fleming and Rachel Lowenstein, co-founder and chief creative officer of the Neu Project, a creative consultancy.Music: “Deep Reflection” by DP and Triple Scoop Music. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In April 2025, the Idaho Medical Freedom Act was passed. Leslie Manookian of the Health Freedom Defense Fund crafted the legislation and lobbied for it to become law, in order to protect residents of Idaho from being fired, excluded, or discriminated against for not taking or using a medical intervention. What if you could pass similar legislation where you live? Would you like insights on how to preserve medical freedom for you and your community?   Leslie today gives us the back story on what motivated her in the first place to help her fellow Idahoans. And she describes the hurdles she faced as she pushed to get the act passed. She also discusses how Big Tech has been implicated in the suppression of our freedom, starting way before 2020, and why it's so important to work in our local communities to push back against the encroachment of our freedoms from tech and pharmaceutical companies and the government.   Visit Leslie's website: healthfreedomdefense.org Become a member of the Weston A. Price Foundation (use code pod10) at westonaprice.org Check out our sponsors: Optimal Carnivore and American Blossom Linens  

Sharif-Munir & Trump Meet | Tariff on Pharma | Baloch | Tahir Gora, Gen PR Shankar

America to Fix India! | China Reduces Pharma Tariff on India to 0 | Rail Missile Launch Spooks Pak

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.President Trump has announced a 100% tariff deadline for pharmaceutical companies starting on October 1. However, companies that have already begun construction on manufacturing facilities in the U.S. are exempt from these tariffs. This move is part of the administration's efforts to lower drug prices and improve access to treatments for patients.In other news, Crinetics Pharmaceuticals has received FDA approval for their once-daily treatment for acromegaly, a rare pituitary condition. This approval marks a significant milestone for Crinetics and is expected to have a positive impact on patients' lives.Additionally, Lilly's oral SERD has been approved by the FDA for the treatment of breast cancer. This treatment has shown improved progression-free survival compared to standard therapy, offering new hope for patients battling this disease.The Trump administration is also preparing a proposed rule to further lower drug prices in the U.S., as part of an ongoing effort to align drug prices with other economically similar countries. These developments in the pharmaceutical industry are aimed at improving access to treatments and lowering costs for patients.

Palm oil scandal, pharma tariffs, market jitters - what’s next for global investors? Hosted by Michelle Martin with Ryan Huang, we unpack Wilmar International’s corruption fallout, Donald Trump’s 100% pharma tariffs, and Chugai Pharmaceutical and Novo Nordisk’s market reaction. We explore the Buffett Indicator’s warning on U.S. equities, Nike’s upcoming earnings, and local market movers like Centurion Accommodation REIT, CapitaLand India Trust, and Jardine Matheson. Plus, our daily UP or DOWN verdict on Lululemon, Microsoft, and more. A fast-moving episode on scandals, stocks, and strategy.See omnystudio.com/listener for privacy information.

Pharma stocks plunge as Trump’s 100% tariffs send shockwaves across Asia. Hosted by Michelle Martin, we break down the impact on Singapore’s $4 billion pharma exports, Sumitomo Pharma, CSL, and more. Are these tariffs a short-term blow or a long-term reset for Asian healthcare investments? Plus, we spotlight Mapletree’s three Singapore REITs - Logistics, Industrial, and Pan-Asia Commercial - amid expected rate cuts. Which one offers the best dividend yield and growth potential? Dividend Titan’s Willie Keng shares his strategy for navigating healthcare risks and REIT opportunities. See omnystudio.com/listener for privacy information.

Wall Street ended a three-day losing streak after the latest inflation report, with the Fed’s preferred measure of inflation coming in line with economists’ expectations. This relief saw buyers push most sectors higher. Pharma stocks jumped on tariff news and game maker Electronic Arts surged on reports of a potential $50 billion buyout. Energy shares also led weekly gains ahead of the OPEC meeting. Still, concerns over a possible government shutdown weighed on sentiment heading into the week. Back home, futures point to a modest gain for the ASX 200 on Monday ahead of the RBA’s two-day meeting. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

Support healthy circulation in your body — so you feel energized, clear-headed, and vibrant again. https://www.bloodflow7.com/FlyoverSupport healthy circulation in your body — so you feel energized, clear-headed, and vibrant again. https://www.bloodflow7.com/Flyoverhttps://www.bloodflow7.com/FlyoverTonight at 8:30pm CST, on the Flyover Conservatives show we are tackling the most important things going on RIGHT NOW from a Conservative Christian perspective! Tonight at 8:30pm CST, on the Flyover Conservatives show we are tackling the most important things going on RIGHT NOW from a Conservative Christian perspective! TO WATCH ALL FLYOVER CONTENT: www.theflyoverapp.com TO WATCH ALL FLYOVER CONTENT: www.theflyoverapp.com Follow and Subscribe on YouTube: https://www.youtube.com/@TheFlyoverConservativesShow Follow and Subscribe on YouTube: https://www.youtube.com/@TheFlyoverConservativesShow To Schedule A Time To Talk To Dr. Dr. Kirk Elliott Go To To Schedule A Time To Talk To Dr. Dr. Kirk Elliott Go To ▶ https://flyovergold.com▶ https://flyovergold.comOr Call 720-605-3900 Or Call 720-605-3900 ► Receive your FREE 52 Date Night Ideas Playbook to make date night more exciting, go to www.prosperousmarriage.com► Receive your FREE 52 Date Night Ideas Playbook to make date night more exciting, go to www.prosperousmarriage.comwww.prosperousmarriage.comDr. Troy Spurrill is the founder and CEO of Synapse Center for Health and Healing.  He started Synapse over 26 years ago with a vision to bring an integrative approach to healthcare through functional medicine, making Synapse an internationally known center for true health.Dr. Troy Spurrill is the founder and CEO of Synapse Center for Health and Healing.  He stSend us a message... we can't reply, but we read them all!Support the show► ReAwaken America- text the word FLYOVER to 918-851-0102 (Message and data rates may apply. Terms/privacy: 40509-info.com) ► Kirk Elliott PHD - http://FlyoverGold.com ► My Pillow - https://MyPillow.com/Flyover ► ALL LINKS: https://sociatap.com/FlyoverConservatives

A.M. Edition for Sept. 26. President Trump unveils new levies on branded or patented drugs from pharmaceutical companies that aren't building manufacturing plants in America. Plus, a federal grand jury in Virginia indicted former FBI director James Comey on charges of making false statements and obstruction during the bureau's earlier investigation of the Trump campaign's ties to Russia in the 2016 election. And, WSJ foreign correspondent Sune Rasmussen details the difficulty in defending against drone incursions for NATO, an alliance built for more traditional military conflicts, in a new age of so-called hybrid attacks. Caitlin McCabe hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Want to buy furniture before the holidays? Kitchen cabinets? How about a new truck? They're all being hit by new tariffs next week as well as name brand drugs. Greg and Holly discuss President Trump's latest tariff announcement.

In this episode of Grow Everything, hosts Karl Schmieder and Erum Azeez sit down with Dr. Alessandra Zonari, co-founder and Chief Scientific Officer at OneSkin. Alessandra shares her personal journey from Brazil to biotech, driven by a mission to transform how we think about aging. She explains the science of cellular senescence, the discovery of the groundbreaking OS-1 peptide, and why skin is more than a beauty surface—it's a window into systemic health and longevity. Listeners will hear candid insights into the challenges of translating biotech discoveries into consumer products, the importance of radical transparency in science communication, and where peptides and personalized skincare fit into the future of the longevity movement. This is a must-listen for anyone passionate about synthetic biology, sustainable innovation, and the science of healthy agingGrow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at www.messaginglab.com/groweverythingChapters:(00:00:00) Welcome to Grow Everything Podcast(00:00:18) London's Bio Fab Fair Recap(00:02:34) Biotech's Bottom Line Impact(00:05:49) Pharma's Path to Consumer Products(00:08:00) The Accidental Discovery of Splenda(00:09:26) Meet Dr. Alessandra Zonari(00:10:54) A Scientist's Personal Mission(00:13:15) "Zombie Cells" and Skin Aging(00:16:30) Longevity Science vs. Marketing(00:18:28) The Hunt for the OS-01 Peptide(00:21:39) The Five-Year Path to Market(00:22:49) Science-First Communication(00:28:21) The Challenge of Going to Market(00:31:16) Communicating to Beauty vs. Biotech(00:33:45) The Future: Personalized Peptides(00:36:24) Why Science Storytelling Fails(00:38:42) Advice for Scientist-Founders(00:40:00) Peptide vs. SPF(00:40:42) Busting the Biggest Aging Myth(00:41:11) The Future of Personalized Aging(00:43:33) Why Aging is "Excited"(00:44:15) Actress or Astronaut(00:46:17) Peptides as "Cell Messages"Episode Links:Julie wolf episodeOneSkinTopics Covered: skincare, cellular senescence, peptides, OneSkin, skin health, anti aging  Have a question or comment? Message us here:Text or Call (804) 505-5553

Trump Attacks Pharma with Tariff | India to Cancel Jet Engine Deal | Trump Treating India as Rival

SBS Finance Editor Ricardo Gonçalves speaks with Shane Oliver from AMP and Marcus Bogdan from Blackmore Capital about the reaction to a US decision to apply 100% import tariffs to pharmaceutical products from Wednesday, plus all the latest from the sharemarket.

Pharma stocks in Asia plunge following President Trump slapping tariffs of up to 100 per cent on the sector with the EU avoiding the brunt of the impact due to its trade deal with the U.S. Q2 GDP in the U.S. expands by more than expected, notching the fastest pace of growth in almost two years. President Trump signs an executive order to keep TikTok operational Stateside. The company is valued at $14bn but Beijing avoids commenting on the deal. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The CDC recommends changes to MMRV vaccine use; Trump administration claims acetaminophen linked to autism; first Barth syndrome treatment gets green light; gene therapy looks promising for Huntington disease; and a new SC formulation of Keytruda gains approval.

Die Zölle sollen für patentierte Arzneimittel gelten, die nicht in den USA produziert werden. Das dürfte auch die Schweizer Exportwirtschaft treffen, denn gut die Hälfte der Schweizer Exporte in die USA derzeit sind Pharmazeutika. Weitere Themen: · Der frühere Direktor der US-Bundespolizei FBI, James Comey, ist angeklagt worden. Comey hat in der ersten Amtszeit von Donald Trump mögliche Verbindungen zwischen Russland und dem Wahlkampfteam des US-Präsidenten untersucht. · Die Video-App Tiktok muss in den USA verkauft werden. In der Nacht hat die US-Regierung die Eckpunkte festgelegt. Das US-Geschäft wird mit rund 14 Milliarden Dollar bewertet. · Auch diese Nacht wurden wieder Drohnen über Dänemark gesichtet. Dieses Mal war der Flughafen Aalborg betroffen, der kurzzeitig geschlossen werden musste.

US President Trump announced 100% tariffs on Pharmaceuticals, 50% tariffs on all Kitchen Cabinets, Bathroom Vanities, and associated products, a 30% tariff on Upholstered Furniture, and a 25% tariff will be imposed on all “Heavy Trucks” made in other parts of the world.European bourses seemingly shrug off Trump's latest barrage of tariffs; US equity futures trade tentatively into US PCE.USD rally pauses for breath ahead of PCE; EUR unmoved by ECB Survey of Consumer Expectations, which saw the 1- and 5-year forecasts rise.Crude is slightly lower in very quiet trade, XAU/USTs are rangebound awaiting data.Looking ahead, US PCE (Aug), US University of Michigan Final (Sep), Fed's Barkin, Bowman.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

US President Trump announced 100% tariffs on Pharmaceuticals, 50% tariffs on all Kitchen Cabinets, Bathroom Vanities, and associated products, a 30% tariff on Upholstered Furniture, and a 25% tariff will be imposed on all “Heavy Trucks” made in other parts of the world.US President Trump signed an executive order on TikTok, saying he had good talks with Chinese President Xi and that China is fully on board. EU plans to impose tariffs of 25–50% on Chinese steel and related products, according to Reuters, citing Handelsblatt.APAC stocks traded mostly lower after being subdued for a bulk of the session following a similar performance stateside.European equity futures are indicative of a slightly firmer cash open with the Euro Stoxx 50 future +0.4% after cash closed -0.3% on Thursday.Looking ahead, highlights include US PCE (Aug), US University of Michigan Final (Sep), ECB's Cipollone, Lagarde, Fed's Barkin, Bowman, and supply from Italy.Click for the Newsquawk Week Ahead.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Ari Paparo and Eric Franchi speak with Josh Walsh, founder and CEO of BranchLab, about how pharmaceutical advertising is changing. The discussion covers BranchLab's use of neural networks with non-health data, the impact of new privacy regulations, and recent funding from Lance Armstrong's Next Ventures. The conversation also touches on Deep Intent's acquisition, ongoing federal policy debates, and the broader implications for healthcare marketing. Takeaways BranchLab's Model: Neural networks trained on non-health data can help address privacy concerns while enabling audience insights. Funding Story: Next Ventures, led by Lance Armstrong, invested in BranchLab as part of a mission to support healthcare transformation. Industry Valuation: Deep Intent's $637M sale demonstrates the scale of opportunity in pharma marketing technology. Regulatory Shifts: State laws like Washington's My Health, My Data and New York's S929 are influencing how data can be used in advertising. Federal Policy Outlook: A nationwide ban on pharma ads is unlikely, but new disclosure and targeting requirements may emerge. Public Health Link: Responsible advertising can encourage more patient-doctor interactions, which often align with improved outcomes. Chapters 00:00 – Introductions02:00 – What BranchLab Does05:00 – Funding from Next Ventures07:30 – Industry Context09:30 – Data and Privacy13:00 – Federal Policy16:30 – The Road Ahead20:00 – Wrap-Up Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world.## Immuneering's drug atebimetinib has shown promising results in doubling overall survival in pancreatic cancer patients after nine months. Truist analysts have deemed the results encouraging, although some unknowns remain in the data. Immuneering plans to initiate a registrational trial for atebimetinib later this year. ## In other news, Lilly has halted a mid-stage obesity study for strategic reasons, Harmony has failed a pivotal trial for fragile X syndrome, and the FDA has released guidance to streamline the development of cell and gene therapies. Overall, Immuneering's drug shows potential in improving survival rates for pancreatic cancer patients, with further trials planned for the future.

From Episode #212: “Is Tylenol Linked to Autism? & A Drug Ad Crackdown"Access the FULL Episode HERE: https://beyondlabels.supportingcast.fm/Follow on InstagramFollow on XSubscribe on RumbleSubscribe on YouTubeFind Joel Here: www.polyfacefarms.comFind Sina Here: www.drsinamccullough.comDISCLAIMER

Ten billion dollars in pharma advertising just got a whole lot less effective. With Trump's new memo cracking down on DTC ads—TV, social, digital, influencers, even online pharmacies—your pipeline may be at risk. In this episode of the Spin Sucks Podcast, Gini Dietrich explains why disclosure-heavy ads will crush acquisition costs, how competitors are already shifting to PESO Model® strategies, and what you can do now to protect your market share. Don't wait until your board or investors start asking questions. The brands that move today will be taking market share by March.

CannCon and Ghost take on a packed Tuesday edition of Badlands Daily, starting with Trump's explosive announcement linking Tylenol use in pregnancy to autism, sparking Big Pharma denials and possible lawsuits. The hosts dig into vaccine safety, censorship, and the broader fight against medical corruption, drawing comparisons to Nuremberg accountability. They then tackle a messy drug pricing controversy, exposing how media spin distorts Trump's push for fairness in global markets. Shifting gears, the show dives into MSNBC's hit piece on Tom Homan, FBI entrapment, and CIA-fed narratives, followed by Trump's executive order designating Antifa a domestic terror group. From looming government shutdown games in Congress to SCOTUS weighing presidential power over “independent” agencies, CannCon and Ghost emphasize first principles and accountability. Internationally, they cover Trump's moves with Turkey, Netanyahu, and Kazakhstan, plus the UN's recognition of Palestine, setting the stage for geopolitical realignment. With sharp commentary and no-nonsense analysis, this episode threads together corruption, propaganda, and global maneuvering.

TODAY ON THE ROBERT SCOTT BELL SHOW: ACIP Recommends MMR Delays, Dr. Bahlman, Chiropractic health, Pet care, Natrum Arsenicosum, Saturated Fat War, Newborn Hep B Agenda, Food Emancipation Proclamation, Pharma vs. Kids, Human Composting in Jersey and MORE! https://robertscottbell.com/acip-recommends-mmr-delays-dr-bahlman-chiropractor-nutrition-practitioner-natrum-arsenicosum-saturated-fat-war-newborn-hep-b-agenda-food-emancipation-proclamation-pharma-vs-kids-human-compos/https://boxcast.tv/view/acip-recommends-mmr-delays-dr-bahlman-chiropractic-health-pet-care-newborn-hep-b-agenda---the-rsb-show-9-19-25-mcjumpelm6qtghaaoosf Please read this disclaimer carefully before you (“you”, “your”) use our [Your Website URL] website (“website”, “service”) operated by the [Your Business Name] (“operator”, “us”, “we”, “our”). Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

Pharmaceutical giant AstraZeneca has paused a £200m investment in Britain and could move its primary listing to America. Can the UK maintain its status as a “life-science superpower”? Why autonomous air wings are the future of war in the sky. And how scientists in the Caribbean are restoring the barrier reef through “coral IVF”. Listen to what matters most, from global politics and business to science and technology—Subscribe to Economist Podcasts+For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.

Pharmaceutical giant AstraZeneca has paused a £200m investment in Britain and could move its primary listing to America. Can the UK maintain its status as a “life-science superpower”? Why autonomous air wings are the future of war in the sky. And how scientists in the Caribbean are restoring the barrier reef through “coral IVF”. Listen to what matters most, from global politics and business to science and technology—Subscribe to Economist Podcasts+For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.

In this episode, we revisit the critical topic of America's pharmaceutical industry with Iowa Congresswoman Mariannette Miller-Meeks. Join us as we discuss the recent steps taken by President Trump to bring pharmaceutical manufacturing back to the U.S., the challenges of drug shortages, and the innovative measures being proposed to ensure a stable supply chain. Discover how regulatory relief, tax provisions, and the role of pharmacy benefit managers are shaping the future of pharmaceuticals in America. Next, we explore the urgent need for reshoring America's drug manufacturing with industry leaders David Shook and Craig Henahan. Discover the complexities of sourcing generic pharmaceuticals, the challenges posed by outsourcing, and the innovative solutions being developed to bring essential drug production back to the U.S. Finally, we welcome David Bozell, president of the Media Research Center, to discuss the current state of journalism in America. Together, we dissect recent controversial comments made by media figures and explore the implications of their rhetoric. David shares insights on how the media landscape has changed, particularly in the wake of political events and social tensions. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.